AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.
More Information Supplier Page
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.
More Information Supplier Page
JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.
More Information Supplier Page
JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.
More Information Supplier Page 
ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
More Information Supplier Page
ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
More Information Supplier Page
ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
More Information Supplier Page ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
More Information Supplier Page 
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier Page
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier Page 
